Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved an indication extension of IMBRUVICA (ibrutinib) in ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according ...

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the ...

Rash isn’t the most common symptom of Hodgkin lymphoma, but oncologists say it can happen. “This is often a rash that will ...

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

Massey Comprehensive Cancer Center is the first U.S. site to enroll patients in a global trial of first-in-class therapy for skin-related T-cell lymphoma -- a rare type of non-Hodgkin lymphoma that ...

If it has seemed like more people you know are developing diabetes, you are right. The diabetes epidemic is not called an ...

A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...